ROBERT CHESS - 18 Sep 2023 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Issuer symbol
NKTR
Transactions as of
18 Sep 2023
Net transactions value
-$6,834
Form type
4
Filing time
20 Sep 2023, 20:08:24 UTC
Previous filing
09 Feb 2023
Next filing
09 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale $6,834 -10,200 -3.6% $0.6700 274,773 22 Sep 2022 Direct F1, F2, F3
holding NKTR Common Stock 2,100 18 Sep 2023 by daughter F4
holding NKTR Common Stock 2,100 18 Sep 2023 by son F4
holding NKTR Common Stock 2,100 18 Sep 2023 by daughter F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +85,000 $0.000000 85,000 19 Sep 2023 Common Stock 85,000 $0.6800 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F3 Includes 56,794 shares previously reported as shares held in Grantor Retained Annuity Trusts for which the reporting person was the sole trustee.
F4 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F5 This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023.